Contact us to find out if we have the data you need. Having offices around the globe, we are open 24 hours a day, 5 days a week with multiple language support. Please visit our Contact page to see which office is open right now!

Summary This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. The more…

Overview Introduction In 2007, HIV drugs achieved sales of $9.3 billion in the 7MM, growing faster than the overall market at a CAGR of 11.3% from 2004-2007. Due to patent exp more…

Overview Introduction Antibody-based agents represent a novel approach to the treatment and prophylaxis of infectious diseases. In recent years, considerable interest has been more…

Research was carried out on the infectious disease pharmaceutical market in key Sub-Saharan countries namely Kenya, Nigeria and Tanzania. A thorough PESTLE (Political, more…

Report Scope and Methodology This report examines China's macroeconomic trends, investment environment; HIV treatment drugs industry assessments, sales volumes and forecasts, more…

US demand to increase 4% annually through 2011 US demand for infection prevention products and services is forecast to rise 4.0 percent annually to $15.6 billion in 2011. more…

Overview Introduction Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial more…

The anti-infectives market is forecast to expand at a CAGR of 4.8%over the period 2005-11, driven largely by gains in the anti-bacterial and anti-viral classes. This more…

The importance, danger and costs of tuberculosis in the 21st century cannot be understated or underestimated. Though nearly extinct in the 20th century, over 1.6 billion more…

This third volume of Kalorama Information's World Market for Anti-Infectives series, the 2nd. Edition focuses on three general product segments of antiviral treatment: Nucleos more…

This series provides total coverage of the Anti-Infectives market, a market that is changing due to product development resistance issues and in some cases, generic more…

Abstract Overview Introduction The influenza vaccine market, sized at approximately $2.2 billion in 2006, yields many challenges. Demand is highly variable, and only l more…

Introduction HIV/AIDS stands out as a highly lucrative and expanding market for diagnostics companies because of the close integration of diagnostics in initial diagnosis and more…

Part of a three volume series. Over one billion people suffer from fungal infections worldwide. Although athlete's foot, dandruff, vaginal yeast infection and fungal nail are more…

This research service looks at the surgical infection control market in Europe, covering the United Kingdom,Germany,France,Italy,Spain,Benelux and Scadinavia.The segments more…

Overview Introduction The HIV market generated $7.4 billion of sales in 2005 and experienced a CAGR of 13.3% from 2001-2005, making it one of the fastest growing infectious di more…

Overview Introduction In the US, approximately 88 million people are diagnosed with a respiratory tract infection in an average year. Of these, a total of 66 million patients more…

This report analyzes the worldwide markets for Antivirals in US$ Million. The major product segments analyzed are HIV Antivirals (Reverse Transcriptase Inhibitors (RTIs) more…

Introduction Antibiotic drug resistance is a perpetual and growing source of medical need; however, diagnostics that can identify drug-resistant pathogens are limited in more…

Overview Introduction More people than ever are living with HIV and AIDS in North America and Western Europe. Over the next five years, a great variety of new HIV drugs are ex more…

Global sales of anti-infective drugs reached $44.5 billion in 2005 and will likely double over the next 5 years. Antibiotics led the category at $31 billion. Infectious more…

The purpose of this TriMark Publications report is to describe the threatening world pandemic caused by avian influenza, also known as bird flu. This report discusses the more…

Antiviral Therapeutics: Pipelines and Competitive Dynamics assesses the compounds, the clinical data, the companies, and the market-shifting developments in the antiviral more…

TB is epidemic in many developing countries, owing in part to co-infection with HIV and the emergence and spread of multidrug-resistant strains of TB (MDR-TB). The general more…

This Frost & Sullivan research service titled HIV Drug Developments - Emerging Technologies provides information on HIV drugs, vaccines, and the microbicides sector. The study more…

Overview Introduction An estimated 10 million people in the seven major markets have chronic HCV. The current standard of care, pegylated interferon (Peg-IFN) plus ribavirin ( more…

Research Overview This Frost & Sullivan research service entitled Latin American Rapid Tests Market for Infectious Diseases provides an overview on the Latin American region more…

REPORT HIGHLIGHTS By 2010, the worldwide influenza market is likely to reach $7.1 billion, with average annual growth estimated at 19.8%. The worldwide influenza market is es more…

This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years more…

Partneringdesk Deals and alliances in infectious diseases Partneringdesk deals and alliances in infectious diseases provides an in-depth view of over 1600 deals and alliances more…

Market Overview The U.S. infectious disease diagnostics market will play a significant role in the dynamic IVD market. This market is segmented according to molecular, more…

Overview Introduction Sepsis, a complex and rapidly progressing disease with up to 80% associated mortality, presents major challenges with regard to its epidemiology, definit more…

The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges more…

The U.S. Market for OTC anti-infective products surpassed the $2 billion mark last year. Although overall growth is sluggish, the market is a proven revenue source for a more…

Overview Introduction Hepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally. HBV va more…

Overview Introduction The global incidence of STIs is estimated at several hundreds of millions cases per year, and due to the asymptomatic nature of most infections, underrep more…

This volume of Kalorama Information's World Market for Anti-Infectives series focuses on three general product segments of antiviral treatment: Nucleoside Analogs Protease In more…

Tropical diseases account for around 5 million deaths per year (WHO, 2002). Major contributors to these numbers are the mosquito borne diseases, which include West Nile Fever, more…

Scope of this report is the changing epidemiology of HIV is discussed, as well as the changing unmet needs that are currently presenting themselves more…

Review of expanded access programs, including numbers, location, length oftime and range of participants more…

Maintaining Profitability Proves Challenging in the Toll-free Services Market Intense competition among service providers in the toll-free services market has been exerting a more…

This unique product offering provides an analysis of changing market conditions and strategic future outlook using the gold standard IMS Health sales data, an unrivalled more…

In December 2004, 35.9-44.3 million individuals were currently living withHIV/AIDS. more…

Respondents have been chosen randomly in order to guarantee that the respondents reflect the real market situation. However the definition of the project required the focus on more…

The HIV market is analyzed in detail on a country basis (including the US, EU5 and Japan), with historic and forecast sales from 1999 to 2014 provided more…

Urinary tract infections are one of the most common bacterial infections across the seven major markets, second only to respiratory tract infections. As a result, such more…

Bacterial skin and skin structure infections are among the most common infections treated within the community setting. There are a wide range of different types of infection, more…

Fueled by the growing interest in neuropathic pain but keen to avoid competition with larger players, small companies recognize the commercial opportunity of the HIV-related more…

This report, the final volume of the Diagnostics for Emerging Infectious Disease Threats series, focuses on diagnostic testing for 11 bacterial and protozoal diseases in more…

This report analyses the fluoroquinolone class as a whole and detailed profiles of leading class members. more…

Systemic fungal infections lead to considerable morbidity and mortality in patients with suppressed immune systems, such as HIV, cancer and transplant patients. more…

Scope of this report is key data and epidemiology of the seven major HIV therapeutic markets highlighting the HIV / HBV co-morbid population more…

This report focuses on diagnostic testing for 10 emerging viral infectious diseases more…

Antibacterial prescription patterns within the hospital setting are distinct from those seen within the community. more…

Antiviral drugs are the main, if only, method of treatment of major viral disease conditions. more…

This report focuses on the prion diagnostic technologies that are being used worldwide, developing technologies, the different types of prion testing, and the policies that more…

While each viral indication, ranging from HIV to influenza, presents unique challenges, there are a number of issues that companies developing and marketing drugs across this more…

The HIV and hepatitis C (HCV) treatment markets are among the fastest growing infectious disease sectors. As co-infection with HIV and HCV is becoming increasingly common, as more…

The antibacterial market is the largest infectious disease sector, in terms of both revenue and prescription volume. Although older highly genericised products are still more…

Over the next 5 years, key products across the major infectious disease sectors are set to face patent expiry. With generics manufacturers lining up to produce cheaper more…

Increasing drug-resistance, alongside growing competition and increasing costs of discovery, is decreasing the incentive to invest in novel antibacterial product development. more…

With a focus on the commercial environment within the HIV sector in the USA, this Analysis investigates key market characteristics and the strategies required to improve more…

As the superficial fungal infection market becomes increasingly genericized, with two key patent expiries in 2004, market leaders need to adopt effective life-cycle management more…

The Hepatitis markets have high patient potential, despite declining transmission rates. In addition, the current treatments available are not efficacious in the majority of more…

The antibacterial market is one of high value, representing an area of substantial interest for novel products. The causative pathogens, site of infection and epidemiology of more…

SARS, the severe acute respiratory syndrome, is a global health emergency of the highest order and it's not at all clear yet if it represents a commercial opportunity. more…

he second volume of Kalorama' s ongoing market study on anti-infectives tackles this large and dynamic segment with a global report on the clinical, regulatory, business, and more…

This brief provides an overview of HIV drug pricing strategies in the US and UK. The US market represents the largest and most interesting market for the pharmaceutical more…

Provides an account of all the key market events that took place during November 2002. Key events include new product launches, clinical trial data and conference findings. more…

Provides an account of all the key market events that took place during march 2003. Key events include new product launches, clinical trial data and conference findings. Key more…

The launch, and disappointing sales, of Lilly's sepsis treatment, Xigris (drotrecogin alpha), has emphasized the complexity of the sepsis market, acting as a wake-up call for more…

The HIV sector is experiencing a slowdown following high growth rates during its early years, but the R&D pipeline is set to deliver products onto the market to 2010 with the more…

The new management report "The Antivirals Outlook to 2007: Marketing opportunities by disease state, patient potential and product profile', is a single source guide to all more…

This report explores the need for more effective drugs to treat serious systemic fungal infections (particularly in immunocompromised individuals), as well as drugs that more…

The HIV pandemic of 10-15 years ago spurred significant excitement and activity in the development of novel antifungal products to meet the sudden increase in patient more…